|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Letters to the Editor |
*Department of Endo and Vascular Surgery, University Hospital "Sestre Milosrdnice", Vinogradska 29, 10000 Zagreb, Croatia
Received 16 January 2008; accepted 25 January 2008.
* Corresponding author. Tel.: +385 1 46 40 774; fax: +385 1 38 62 292. (Email: narcis.hudorovic@zg.htnet.hr).
Key Words: Cardiovascular disease Risk factors Statins
| The first 20% of the full text of this article appears below. |
The extraordinary actuality of the article of Paraskevas [1] is my excuse for this letter. Patients presenting for major cardiovascular surgery represent a dynamic challenge for the surgeon that extends beyond the intricacies of the planned operation. These patients frequently suffer from other significant comorbidities such as diabetes, respiratory, renal disease and elevated cholesterol. The management of these patients has to address not only immediate perioperative management issues but also prevent the deterioration of coexisting disease.
The growing body of evidence for such patients confirms that aggressive comprehensive risk factor management improves survival, reduces recurrent events and the need for interventional procedures,
This article has been cited by other articles:
![]() |
K. I. Paraskevas Reply to HudorovicWould a randomized controlled trial testing the effects of statins on patients undergoing cardiothoracic surgery be ethical? Eur. J. Cardiothorac. Surg., May 1, 2008; 33(5): 948 - 948. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |